Scotiabank Raises Bristol-Myers (BMY) PT to $60 Citing Catalyst-Rich 2026 Growth

Bristol-Myers Squibb Company (NYSE:BMY) is one of the cheap stocks to buy for the next 3 years. On January 9, Scotiabank analyst Louise Chen raised the firm’s price target on Bristol-Myers to $60 from $53, while maintaining a Sector Perform rating on the shares. With the stock trading at an inexpensive valuation and several key milestones on the horizon, the firm views the upcoming catalyst-rich year as a strong buying opportunity. In other news, on December 11, the FDA granted Priority Review to Bristol ...